This possibly explains that neurodegenerative disorders such as Alzheimer’s disease and related dementias have been explored for determining the neuroprotective potential of GPR55-targeting compounds only recently [69,70], whereas movement-related disorders, in particular PD, are within those neurodegenerative pathologies investigated earlier and more extensively in relation with the GPR55 ligands [51,52,71,72]. This evidence concerns the gene GPR55 and early-onset autosomal dominant Alzheimer disease.